Skip to main content
NCBI home page
Journal of Atherosclerosis and Thrombosis logoLink to Journal of Atherosclerosis and Thrombosis
. 2024 Nov 16;32(2):111–119. doi: 10.5551/jat.RV22030

Atherosclerotic Diseases in Chronic Kidney Disease

Toshiaki Nakano 1
PMCID: PMC11802252  PMID: 39551490

Abstract

Patients with chronic kidney disease (CKD) have a high incidence of atherosclerotic diseases, such as ischemic heart disease, cerebrovascular disease, and peripheral arterial disease. To prevent the incidence of atherosclerotic cardiovascular disease in patients with CKD, the pathology of arteriosclerosis should be determined. Vascular calcification is a characteristic of arteriosclerosis in patients with CKD. Recent studies have reported that coronary artery calcification is associated with acute coronary syndromes. CKD is frequently associated with heart failure. Furthermore, recent evidence suggests that coronary artery calcification affects asymptomatic myocardial ischemia. Hyperphosphatemia and calciprotein particles may be involved in the pathology of vascular calcification. Controlling the progression of vascular calcification and classical atherosclerotic risk factors is important to prevent the occurrence of atherosclerotic diseases in CKD.

Keywords: Atherosclerotic disease, Chronic kidney disease, Vascular calcification, Hyperphosphatemia

I. Introduction

The number of patients with chronic kidney disease (CKD) has been increasing along with an increase in lifestyle-related diseases and the population 1 , 2) . Patients with CKD appear to have a higher incidence of cardiovascular complications than a population with a normal kidney function. Therefore, lipid-lowering therapies such as statins have been considered to prevent the development of atherosclerotic cardiovascular disease (ASCVD) 3) . The fact that the effect of lipid-lowering therapy using statins in reducing atherosclerotic cardiovascular events diminishes as CKD progresses to end-stage renal failure suggests that the pathology of atherosclerosis in patients with CKD may be altered 4 , 5) .

In recent years, evidence has suggested that vascular calcification affects plaque rupture and calcified nodules and exacerbates the development of acute coronary syndrome 6) . In addition, coronary artery calcification may cause microcirculatory disturbances in the heart 7) . This review summarizes the epidemiological and pathological characteristics of ASCVD associated with CKD.

II. Epidemiology of Cardiovascular disease in patients with CKD

In a large cohort study, the incidence of cardiovascular disease was 36.6 times higher in a population with a low estimated glomerular filtration rate (eGFR) of 15 ml/min/1.73 m2 than in a population with a normal kidney function 8) . In addition, the incidence of cardiovascular disease was 3.4 times higher after multivariate adjusting for risk factors than that in a population with a normal kidney function. A cohort study of the general Japanese population similarly reported that CKD is an independent risk factor for the development of cardiovascular disease 9) . Several other reports have shown that CKD and proteinuria are independent risk factors for the development of cardiovascular disease and death 10 - 12) .

Common risk factors for CKD and cardiovascular diseases, such as hypertension, diabetes, and dyslipidemia, increase the risk of cardiovascular complications in CKD patients ( Fig.1 ) . In the Suita Study, a multivariate adjusted analysis (adjusted for age, sex, smoking, diabetes, hypertension, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol) showed that the incidence of coronary artery disease was 1.34 times higher in CKD stage 3 and 4.01 times higher in CKD stages 4 and 5 than in the general population 13) . Therefore, the risk of developing coronary artery disease due to CKD remains even after multivariate adjusting for the classical risk factors for atherosclerosis. This finding may be explained by the fact that CKD has various risk factors for cardiovascular disease, such as abnormal calcium and phosphorus metabolism, anemia, accumulation of urea toxins, oxidative stress, chronic inflammation, endothelial dysfunction, increased renin–angiotensin system (RAS) activity, and an increased sympathetic nerve function 14 - 16) ( Table 1 , Fig.1 ) .

Fig.1. Interaction between CKD and ASCVD.

Fig.1. Interaction between CKD and ASCVD

Open in a new tab

Classical risk factors for ASCVD include the progression of atherosclerosis, CKD, heart disease, and stroke. CKD-specific risk factors also affect the progression of atherosclerosis, heart disease, and strokes. CKD, chronic kidney disease; ASCVD, atherosclerotic cardiovascular disease; CKD-MBD, chronic kidney disease-mineral bone disorder.

Table 1. Risk factors for atherosclerosis in patients with CKD.

Classical risk factor Specific risk factor in CKD
Age Mineral bone metabolism
Male gender Vascular calcification
Hypertension Uremic toxin
Diabetes mellitus Renal anemia
Dyslipidemia Oxidative stress
Obesity Chronic Inflammation
Smoking Abnormal lipid modifications
Endothelial dysfunction
Renin angiotensin activity
Sympathetic nerve activity
Open in a new tab

Patients on dialysis have a higher incidence of ASCVD than the general population 17) . Lipid-lowering therapy with statins has been used for patients with CKD. In a clinical trial, a post hoc analysis of pre-dialysis CKD patients showed that statins were effective 3) . However, statins alone failed to prevent cardiovascular events in patients undergoing dialysis 4 , 5) . Therefore, risk factors for atherosclerotic diseases other than dyslipidemia may be involved in patients undergoing dialysis.

III. Frequency of Coronary Artery Disease and Coronary Artery Calcification in Patients with CKD

Ischemic heart disease is a relatively frequent complication in CKD patients. According to the Japanese Society for Dialysis Therapy, myocardial infarction accounted for 3.3% of the causes of death among patients on dialysis in Japan in 2022, which was lower than that in previous years 18) . Deaths directly caused by myocardial infarction have been decreasing owing to the increased use of RAS system inhibitors and statins, therapeutic interventions for renal anemia, and early screening for cardiac diseases. However, regarding a history of ischemic heart disease in predialysis patients with CKD, recent reports from Japan showed a prevalence of 13.4% in the CKD-JAC Study and 10.8% in the Fukuoka Kidney disease Registry Study 19 , 20) . This finding indicates that ischemic heart disease is a frequent complication of chronic kidney disease. A study of myocardial scintigraphy to screen for ischemic heart disease before the induction of dialysis was performed in Japan 21) . This study reported that 22% of the patients with end-stage renal failure had ischemic heart disease, and the frequency of complications remained high. An autopsy study showed that advanced atherosclerotic lesions in the coronary arteries increased with CKD stage progression 22) ( Fig.2 ) . Therefore, the prevention of ischemic heart disease remains an important issue in patients with CKD.

Fig.2. Proportions of atherosclerotic lesions in accordance with the AHA classification associated with the kidney function.

Fig.2. Proportions of atherosclerotic lesions in accordance with the AHA classification associated with the kidney function

Open in a new tab

The bar graphs indicate the percentage of atherosclerotic lesions estimated based on the AHA classifications according to different eGFRs. The percentages of advanced atherosclerosis (AHA types IV–VI) for the respective eGFRs are shown on the right side of the graphs. The figure was reproduced from an article by Nakano et al. 22) with permission from the publisher.

A study that evaluated coronary artery calcification in patients with CKD who underwent chest computed tomography reported that a higher degree of vascular calcification in the coronary arteries was associated with a poorer survival rate 23) . Vascular calcification can occur in the intima and the tunica media. Calcification in the tunica media is called Mönckeberg medial calcific sclerosis and is characteristic of patients with CKD and diabetes, often being found in muscular arteries of the upper and lower extremities and pelvic arteries 24) . However, calcification in the intima often occurs with atherosclerosis and has been reported to be associated with a poorer prognosis than medial calcification 25) . Although the frequency of medial and intimal calcification in the coronary arteries of patients with CKD is unclear, calcification in the intima of coronary arteries is reported to occur with atherosclerosis in patients with CKD 22 , 26) . The frequency of vascular calcification in the coronary arteries was reported in autopsy cases in the Hisayama Study 2 , 22) . In the present study, patients with CKD and an eGFR ＜30 mL/min/1.73 m2 had a 4.7-fold increased risk of coronary artery calcification compared with the general population with an eGFR ≥ 60 mL/min/1.73 m 2 22) . Therefore, patients with CKD have an increased frequency of coronary artery calcification, which may be associated with coronary artery disease.

IV. Pathogenesis of Acute Coronary Syndrome with Coronary Calcification

Acute coronary syndrome is mainly caused by plaque rupture, plaque erosion, and calcified nodules. The most common cause of acute coronary syndrome is plaque rupture, in which rupture of the atheroma results in thrombus formation in the coronary artery. Plaque erosion, in which a thrombus forms on the intimal surface of the plaque, occludes the coronary artery 27) . Risk factors for plaque rupture include a large lipid core, thin fibrous capsule, high inflammatory cell infiltrates, high levels of angiogenesis, enlarged necrotic core, and positive remodeling 28) . Recently, coronary calcification was reported to be associated with plaque rupture 29) . It is difficult to determine whether or not calcification in the intima of coronary arteries directly affects plaque rupture. However, in a previous study, optical coherence tomography during coronary angiography to evaluate the responsible lesion showed that coronary arteries with plaque rupture had spotty calcification in the intima 30) . This finding suggests that microcalcifications and fragmented calcifications in the intima may be risk factors for plaque ruptures.

Thin-cap fibroatheroma and ruptured plaques with a thin fibrous capsule, which are at high risk of rupture, are often associated with microcalcifications (between 0.5 and 15 µm) and fragmented calcifications (＜3 mm) in the intima 27 , 29) . Sheet calcification (＞3 mm) is frequently observed in healed plaque ruptures and fibrocalcific plaques and may be associated with stable plaques with a low risk of rupture 27 , 29) . An autopsy study showed that vascular calcification was associated with intraplaque hemorrhage, which is a risk factor for plaque destabilization 31) ( Fig.3 ) . Macrophage infiltration is also associated with the risk of intraplaque hemorrhage and vascular calcification 31) . These findings suggest that vascular calcification increases the frequency of ASCVD events in patients with advanced atherosclerotic lesions.

Fig.3. Representative images of coronary arteries with calcification and the frequency of intraplaque hemorrhage.

Fig.3. Representative images of coronary arteries with calcification and the frequency of intraplaque hemorrhage

Open in a new tab

(A) Coronary artery with calcification and massive hemorrhage (indicated by an asterisk). The calcification area is 0.83 mm2. (B) Coronary artery with moderate calcification and moderate hemorrhage (asterisk). The calcification area is 1.68 mm2. (C) Coronary artery with moderate calcification, necrosis, and a small amount of hemorrhage (asterisk). The calcification area is 3.24 mm2. (D) Coronary artery with a large calcification area. There is no intraplaque hemorrhage. The calcification area is 5.56 mm2. Arrowheads in the images show the calcification area (A–D). Scale bars indicate 1.0 mm (A–D). (E) The multivariable-adjusted model was adjusted for age, sex, estimated glomerular filtration rate, systolic blood pressure, diabetes, serum total cholesterol concentrations, serum high-density lipoprotein cholesterol concentrations, calcium concentrations, phosphate concentrations, hemoglobin concentrations, current smoking, and current drinking. The solid line represents the adjusted odds ratio, and the dotted line represents the 95% CI. The calcification area at the highest odds ratio for intraplaque hemorrhage was 1.98 mm2. The images were reproduced from an article by Nakano et al. 31) . CI, confidence interval.

Recently, calcified nodules protruding into the lumen of coronary arteries have been shown to cause thrombosis 6) . Necrotic cores in fibroatheroma may become extensively calcified (sheet calcification) over time, forming fibrocalcific plaques. Mechanical stress on diffuse calcified arteries is thought to destroy plate calcification, forming calcified nodules by aggregation of a necrotic core and calcification ( Fig.4 ) . Calcified nodules are often observed in patients with CKD, and balloon intervention often does not provide sufficient dilation for stenotic lesions around calcified nodules in the coronary arteries. Even when stenotic lesions are dilated, calcified nodules may reappear in the stent, causing thrombosis and restenosis.

Fig.4. Atherosclerotic lesions with calcification in CKD.

Fig.4. Atherosclerotic lesions with calcification in CKD

Open in a new tab

(A) CPPs in vessels induce an inflammatory response in macrophages, endothelial cells, and smooth muscle cells. Blue stars indicate CPPs. (B) Calcification in the intima is often associated with intraplaque hemorrhage. (C) A calcified nodule protrudes into the lumen, disrupting the fibrous cap, and is associated with thrombus formation. CPPs, calciprotein particles.

Therefore, calcification in coronary arteries is a risk factor for plaque rupture, and the formation of calcified nodules can lead to thrombus formation in the lumen, resulting in acute coronary syndrome.

V. Heart Failure Associated with CKD

CKD is frequently associated with left ventricular hypertrophy, especially afferent left ventricular hypertrophy 32 , 33) . This condition may be due to the fact that hypertension is more frequently complicated by impaired sodium excretion with a decreased kidney function than a normal kidney function, resulting in an increased frequency of left ventricular hypertrophy. In a recent autopsy study, left ventricular wall thickening increased as CKD progressed, and considerable left ventricular wall thickening was observed even after adjusting for risk factors such as hypertension and diabetes mellitus 34) . Furthermore, an evaluation of myocardial fibrosis showed expansion of fibrosis in myocardial tissue with the progression of the CKD stage. Myocardial wall thickening was also shown to be accompanied by swelling of myocytes, suggesting that local RAS is activated in myocytes 35) . Myocardial fibrosis may also indicate the presence of peripheral circulatory disturbances within the myocardium. CKD pathogenesis is accompanied by abnormal calcium and phosphorus metabolism, which is associated with an increased frequency of calcification in the vascular intima and medial lesions. Such calcification of the vessel wall contributes to increased arterial stiffness and left ventricular hypertrophy 36) . In addition, peripheral myocardial tissue has a high risk of ischemia owing to increased vascular stiffness with calcification, leading to fibrosis and an increased risk of heart failure. Therefore, CKD may predispose patients to left ventricular hypertrophy and myocardial fibrosis.

VI. Coronary Microcirculatory Dysfunction and Coronary Artery Calcification

In recent years, there has been widespread implementation of emergency coronary angiography for acute coronary syndrome, with the development of diagnostic techniques using highly sensitive troponin. This has led to the proposal of a new concept of myocardial infarction without nonobstructive coronary arteries (MINOCA) and ischemia with nonobstructive coronary artery disease (INOCA) 37) . MINOCA occurs not only in patients with heart failure or atrial fibrillation but also in patients with cerebrovascular disease, peripheral arterial disease, and CKD 38) . The main causes of INOCA are coronary spasms and microvascular dysfunction. Coronary microvascular dysfunction frequently occurs in the hearts of patients with CKD 39) .

One study evaluated asymptomatic myocardial ischemia in patients on hemodialysis without a history of ischemic heart disease using fatty acid metabolic scintigraphy 40) . Fatty acid metabolism is frequently impaired in the presence of myocardial ischemia in patients on hemodialysis, which suggests that asymptomatic myocardial ischemia (i.e. INOCA) is more common in the hearts of patients on dialysis than the general population. Furthermore, studies that measured coronary flow reserve (CFR) reported that CFR was lower in patients with CKD than in those without CKD 39) . Patients with CKD have an impaired vascular endothelial function, which may contribute to a reduced CFR. Another study reported an inverse correlation between the degree of coronary artery calcification and CFR 7) . These findings suggest that the frequency of coronary microvascular dysfunction is high in CKD patients. In addition, coronary microvascular dysfunction may be caused by impaired vasodilation due to impaired vascular endothelial function and increased vascular resistance due to vascular calcification. Therefore, vascular calcification may also affect myocardial circulatory disturbances.

VII. Cerebrovascular Complications Associated with CKD

Patients with CKD are at a higher risk of developing cerebrovascular disease than those without CKD. A meta-analysis of CKD and cerebrovascular disease reported a 7% increase in the risk of cerebrovascular disease for every 10 mL/min/1.73 m² decrease in the eGFR 41) . In addition, the appearance of microalbuminuria was reported to increase the risk of cerebrovascular disease 1.53-fold, while overt albuminuria was reported to increase the risk 1.94-fold 41) . A decline in the kidney function, albuminuria, and proteinuria in CKD are risk factors for cerebrovascular disease.

The risk of cerebrovascular disease is further increased in patients undergoing dialysis, with a 5.2-fold higher incidence than that in the general population 17) . Hypertension is the greatest risk factor; however, hyperphosphatemia, which is a characteristic of CKD, is associated with a 2.75-fold increased risk of cerebral hemorrhaging 42) . Renal anemia has also been reported as a risk factor for cerebrovascular disease 43) . These findings suggest that CKD pathophysiology contributes to the risk of cerebrovascular disease.

VIII. Treatment of Cardiovascular Disease in Patients on Dialysis

The DOPPS study showed that patients on dialysis have a high mortality rate 44) . Furthermore, patients on dialysis have a higher incidence of atherosclerotic disease than the general population 17) . Therefore, managing the risk of cardiovascular disease in patients undergoing dialysis is important. In a Q-cohort study of patients on hemodialysis in Japan, those with a systolic blood pressure ≥ 172 mmHg had a higher incidence rate of cardiovascular events than those with systolic blood pressure between 148 to 159 mmHg 45) . Regarding dyslipidemia, cardiovascular events were also increased in patients with total cholesterol concentrations ≥ 178 mg/dL 46) . Therefore, hypertension and dyslipidemia are risk factors for cardiovascular events in patients undergoing dialysis.

Notably, hyperphosphatemia is associated with cerebral hemorrhaging and peripheral arterial disease 42 , 47) . Hyperphosphatemia may cause endothelial dysfunction, and calciprotein particles (CPPs) induced by hyperphosphatemia may induce inflammation in macrophages and vascular smooth muscle cells, leading to atherosclerosis 48) ( Fig.4 ) . In addition, a recently published post hoc analysis of the AURORA study showed that rosuvastatin did not prevent major adverse cardiovascular events in patients on hemodialysis with serum phosphorus concentrations ＞5 mg/dL 49) . However, rosuvastatin reduced major adverse cardiovascular events in patients with serum phosphorus concentrations ＜5 mg/dL. Therefore, hyperphosphatemia may attenuate the effect of statins on the suppression of cardiovascular diseases in patients undergoing hemodialysis. In addition to interventions for classical risk factors, such as hypertension and dyslipidemia, the management of CKD-mineral and bone disorders is also important in treating cardiovascular disease in patients on hemodialysis.

IX. Conclusion

CKD is associated with several risk factors for atherosclerotic diseases, such as hypertension. CKD is also associated with cardiovascular disease owing to the presence of unique pathologies, such as vascular calcification, renal anemia, accumulation of uremic toxins, endothelial dysfunction, and enhancement of the local RAS. In recent years, evidence has suggested that vascular calcification in coronary arteries directly affects acute coronary syndrome or coronary microvascular dysfunction, which in turn may affect MINOCA and INOCA. Hyperphosphatemia has also been implicated in the development of cerebral hemorrhaging and peripheral arterial disease in patients undergoing hemodialysis. Prevention of atherosclerotic disease in patients with CKD requires management of mineral bone metabolism to prevent vascular calcification, in addition to management of classical risk factors, such as hypertension, diabetes, and dyslipidemia.

Acknowledgements

We thank Ellen Knapp, Ph.D., from Edanz (https://jp.edanz.com/ac) for editing the draft of this manuscript.

Conflict of Interest

The author declares no competing interests.

References

  • 1).Levey AS, Coresh J. Chronic kidney disease. Lancet, 2012; 379: 165-180 [DOI] [PubMed] [Google Scholar]
  • 2).Hill NR, Fatoba ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FD. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One, 2016; 11: e0158765 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3).Nakamura H, Mizuno K, Ohashi Y, Yoshida T, Hirao K, Uchida Y, Group MS. Pravastatin and cardiovascular risk in moderate chronic kidney disease. Atherosclerosis, 2009; 206: 512-517 [DOI] [PubMed] [Google Scholar]
  • 4).Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E, German D, Dialysis Study I. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med, 2005; 353: 238-248 [DOI] [PubMed] [Google Scholar]
  • 5).Fellstrom BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Gronhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Suleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wuthrich RP, Gottlow M, Johnsson E, Zannad F, Group AS. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med, 2009; 360: 1395-1407 [DOI] [PubMed] [Google Scholar]
  • 6).Torii S, Sato Y, Otsuka F, Kolodgie FD, Jinnouchi H, Sakamoto A, Park J, Yahagi K, Sakakura K, Cornelissen A, Kawakami R, Mori M, Kawai K, Amoa F, Guo L, Kutyna M, Fernandez R, Romero ME, Fowler D, Finn AV, Virmani R. Eruptive Calcified Nodules as a Potential Mechanism of Acute Coronary Thrombosis and Sudden Death. J Am Coll Cardiol, 2021; 77: 1599-1611 [DOI] [PubMed] [Google Scholar]
  • 7).Caliskan Y, Demirturk M, Ozkok A, Yelken B, Sakaci T, Oflaz H, Unsal A, Yildiz A. Coronary artery calcification and coronary flow velocity in haemodialysis patients. Nephrol Dial Transplant, 2010; 25: 2685-2690 [DOI] [PubMed] [Google Scholar]
  • 8).Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305 [DOI] [PubMed] [Google Scholar]
  • 9).Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int, 2005; 68: 228-236 [DOI] [PubMed] [Google Scholar]
  • 10).Tonelli M, Karumanchi SA, Thadhani R. Epidemiology and Mechanisms of Uremia-Related Cardiovascular Disease. Circulation, 2016; 133: 518-536 [DOI] [PubMed] [Google Scholar]
  • 11).Chronic Kidney Disease Prognosis C, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet, 2010; 375: 2073-2081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12).Kitamura H, Tanaka S, Hiyamuta H, Shimamoto S, Tsuruya K, Nakano T, Kitazono T. Cardiovascular Risk Factor Burden and Treatment Control in Patients with Chronic Kidney Disease: A Cross-Sectional Study. J Atheroscler Thromb, 2023; 30: 1210-1288 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13).Nishimura K, Okamura T, Watanabe M, Nakai M, Takegami M, Higashiyama A, Kokubo Y, Okayama A, Miyamoto Y. Predicting coronary heart disease using risk factor categories for a Japanese urban population, and comparison with the framingham risk score: the suita study. J Atheroscler Thromb, 2014; 21: 784-798 [DOI] [PubMed] [Google Scholar]
  • 14).Iseki K. Stroke feature and management in dialysis patients. Contrib Nephrol, 2013; 179: 100-109 [DOI] [PubMed] [Google Scholar]
  • 15).Valdivielso JM, Rodriguez-Puyol D, Pascual J, Barrios C, Bermudez-Lopez M, Sanchez-Nino MD, Perez-Fernandez M, Ortiz A. Atherosclerosis in Chronic Kidney Disease: More, Less, or Just Different? Arterioscler Thromb Vasc Biol, 2019; 39: 1938-1966 [DOI] [PubMed] [Google Scholar]
  • 16).Nakano T, Katsuki S, Chen M, Decano JL, Halu A, Lee LH, Pestana DVS, Kum AST, Kuromoto RK, Golden WS, Boff MS, Guimaraes GC, Higashi H, Kauffman KJ, Maejima T, Suzuki T, Iwata H, Barabasi AL, Aster JC, Anderson DG, Sharma A, Singh SA, Aikawa E, Aikawa M. Uremic Toxin Indoxyl Sulfate Promotes Proinflammatory Macrophage Activation Via the Interplay of OATP2B1 and Dll4-Notch Signaling. Circulation, 2019; 139: 78-96 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17).Iseki K, Kinjo K, Kimura Y, Osawa A, Fukiyama K. Evidence for high risk of cerebral hemorrhage in chronic dialysis patients. Kidney Int, 1993; 44: 1086-1090 [DOI] [PubMed] [Google Scholar]
  • 18).Hanafusa K. 2022 Annual Dialysis Data Report, JSDT Renal Data Registry. J. Jpn. Soc. Dial. Ther., 2023; 56: 473-536 [Google Scholar]
  • 19).Imai E, Matsuo S, Makino H, Watanabe T, Akizawa T, Nitta K, Iimuro S, Ohashi Y, Hishida A. Chronic Kidney Disease Japan Cohort study: baseline characteristics and factors associated with causative diseases and renal function. Clin Exp Nephrol, 2010; 14: 558-570 [DOI] [PubMed] [Google Scholar]
  • 20).Tanaka S, Nakano T, Hiyamuta H, Tsuruya K, Kitazono T. Association between Multimorbidity and Kidney Function among Patients with Non-Dialysis-Dependent CKD: The Fukuoka Kidney Disease Registry Study. J Atheroscler Thromb, 2022; 29: 1249-1264 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21).Iwasaki M, Joki N, Tanaka Y, Hayashi T, Kubo S, Asakawa T, Matsukane A, Takahashi Y, Hirahata K, Imamura Y, Hase H. Declining prevalence of coronary artery disease in incident dialysis patients over the past two decades. J Atheroscler Thromb, 2014; 21: 593-604 [PubMed] [Google Scholar]
  • 22).Nakano T, Ninomiya T, Sumiyoshi S, Fujii H, Doi Y, Hirakata H, Tsuruya K, Iida M, Kiyohara Y, Sueishi K. Association of kidney function with coronary atherosclerosis and calcification in autopsy samples from Japanese elders: the Hisayama study. Am J Kidney Dis, 2010; 55: 21-30 [DOI] [PubMed] [Google Scholar]
  • 23).Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int, 2007; 71: 438-441 [DOI] [PubMed] [Google Scholar]
  • 24).Micheletti RG, Fishbein GA, Currier JS, Fishbein MC. Monckeberg sclerosis revisited: a clarification of the histologic definition of Monckeberg sclerosis. Arch Pathol Lab Med, 2008; 132: 43-47 [DOI] [PubMed] [Google Scholar]
  • 25).London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant, 2003; 18: 1731-1740 [DOI] [PubMed] [Google Scholar]
  • 26).Nakamura S, Ishibashi-Ueda H, Niizuma S, Yoshihara F, Horio T, Kawano Y. Coronary calcification in patients with chronic kidney disease and coronary artery disease. Clin J Am Soc Nephrol, 2009; 4: 1892-1900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27).Sarnak MJ, Amann K, Bangalore S, Cavalcante JL, Charytan DM, Craig JC, Gill JS, Hlatky MA, Jardine AG, Landmesser U, Newby LK, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, Marwick TH, Conference P. Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review. J Am Coll Cardiol, 2019; 74: 1823-1838 [DOI] [PubMed] [Google Scholar]
  • 28).Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circ Res, 2014; 114: 1852-1866 [DOI] [PubMed] [Google Scholar]
  • 29).Jinnouchi H, Sato Y, Sakamoto A, Cornelissen A, Mori M, Kawakami R, Gadhoke NV, Kolodgie FD, Virmani R, Finn AV. Calcium deposition within coronary atherosclerotic lesion: Implications for plaque stability. Atherosclerosis, 2020; 306: 85-95 [DOI] [PubMed] [Google Scholar]
  • 30).Sakaguchi M, Hasegawa T, Ehara S, Matsumoto K, Mizutani K, Iguchi T, Ishii H, Nakagawa M, Shimada K, Yoshiyama M. New insights into spotty calcification and plaque rupture in acute coronary syndrome: an optical coherence tomography study. Heart Vessels, 2016; 31: 1915-1922 [DOI] [PubMed] [Google Scholar]
  • 31).Nakano T, Kitamura H, Hata J, Maki K, Oda Y, Kitazono T, Ninomiya T. Association between Vascular Calcification and Intraplaque Hemorrhage in Coronary Atherosclerosis from Autopsy: The Hisayama Study. J Atheroscler Thromb, 2024; 31: 1225-1237 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32).Stewart GA, Gansevoort RT, Mark PB, Rooney E, McDonagh TA, Dargie HJ, Stuart R, Rodger C, Jardine AG. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int, 2005; 67: 217-226 [DOI] [PubMed] [Google Scholar]
  • 33).Moran A, Katz R, Jenny NS, Astor B, Bluemke DA, Lima JA, Siscovick D, Bertoni AG, Shlipak MG. Left ventricular hypertrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis, 2008; 52: 839-848 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34).Izumaru K, Hata J, Nakano T, Nakashima Y, Nagata M, Fukuhara M, Oda Y, Kitazono T, Ninomiya T. Reduced Estimated GFR and Cardiac Remodeling: A Population-Based Autopsy Study. Am J Kidney Dis, 2019; 74: 373-381 [DOI] [PubMed] [Google Scholar]
  • 35).Campese VM. Left ventricular function and chronic kidney disease: how soon does it start? Nephrol Dial Transplant, 2014; 29: 1989-1991 [DOI] [PubMed] [Google Scholar]
  • 36).Achinger SG, Ayus JC. Left ventricular hypertrophy: is hyperphosphatemia among dialysis patients a risk factor? J Am Soc Nephrol, 2006; 17: S255-261 [DOI] [PubMed] [Google Scholar]
  • 37).Pepine CJ. ANOCA/INOCA/MINOCA: Open artery ischemia. Am Heart J Plus, 2023; 26 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38).Eggers KM, Hjort M, Baron T, Jernberg T, Nordenskjold AM, Tornvall P, Lindahl B. Morbidity and cause-specific mortality in first-time myocardial infarction with nonobstructive coronary arteries. J Intern Med, 2019; 285: 419-428 [DOI] [PubMed] [Google Scholar]
  • 39).Jain V, Gupta K, Bhatia K, Rajapreyar I, Singh A, Zhou W, Klein A, Nanda NC, Prabhu SD, Bajaj NS. Coronary flow abnormalities in chronic kidney disease: A systematic review and meta-analysis. Echocardiography, 2022; 39: 1382-1390 [DOI] [PubMed] [Google Scholar]
  • 40).Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol, 2008; 51: 139-145 [DOI] [PubMed] [Google Scholar]
  • 41).Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant, 2015; 30: 1162-1169 [DOI] [PubMed] [Google Scholar]
  • 42).Yamada S, Tsuruya K, Taniguchi M, Tokumoto M, Fujisaki K, Hirakata H, Fujimi S, Kitazono T. Association Between Serum Phosphate Levels and Stroke Risk in Patients Undergoing Hemodialysis: The Q-Cohort Study. Stroke, 2016; 47: 2189-2196 [DOI] [PubMed] [Google Scholar]
  • 43).Uchida Y, Nakano T, Kitamura H, Taniguchi M, Tsuruya K, Kitazono T. Association between hyporesponsiveness to erythropoiesis-stimulating agents and risk of brain hemorrhage in patients undergoing hemodialysis: the Q-Cohort Study. Clin Exp Nephrol, 2023; 27: 79-88 [DOI] [PubMed] [Google Scholar]
  • 44).Robinson BM, Bieber B, Pisoni RL, Port FK. Dialysis Outcomes and Practice Patterns Study (DOPPS): its strengths, limitations, and role in informing practices and policies. Clin J Am Soc Nephrol, 2012; 7: 1897-1905 [DOI] [PubMed] [Google Scholar]
  • 45).Hara M, Tanaka S, Taniguchi M, Fujisaki K, Torisu K, Masutani K, Hirakata H, Nakano T, Tsuruya K, Kitazono T. Prognostic value of pre-dialysis blood pressure and risk threshold on clinical outcomes in hemodialysis patients: The Q-Cohort Study. Medicine (Baltimore), 2018; 97: e13485 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46).Nakano T, Hiyamuta H, Yotsueda R, Tanaka S, Taniguchi M, Tsuruya K, Kitazono T. Higher Cholesterol Level Predicts Cardiovascular Event and Inversely Associates With Mortality in Hemodialysis Patients: 10-Year Outcomes of the Q-Cohort Study. Ther Apher Dial, 2020; 24: 431-438 [DOI] [PubMed] [Google Scholar]
  • 47).Shimamoto S, Yamada S, Hiyamuta H, Arase H, Taniguchi M, Tokumoto M, Nakano T, Tsuruya K, Kitazono T. Association of serum phosphate concentration with the incidence of intervention for peripheral artery disease in patients undergoing hemodialysis: 10-year outcomes of the Q-Cohort Study. Atherosclerosis, 2020; 304: 22-29 [DOI] [PubMed] [Google Scholar]
  • 48).Kutikhin AG, Feenstra L, Kostyunin AE, Yuzhalin AE, Hillebrands JL, Krenning G. Calciprotein Particles: Balancing Mineral Homeostasis and Vascular Pathology. Arterioscler Thromb Vasc Biol, 2021; 41: 1607-1624 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49).Massy ZA, Merkling T, Wagner S, Girerd N, Essig M, Wanner C, Fellstrom BC, Rossignol P, Zannad F. Association of Serum Phosphate with Efficacy of Statin Therapy in Hemodialysis Patients. Clin J Am Soc Nephrol, 2022; 17: 546-554 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Atherosclerosis and Thrombosis are provided here courtesy of Japan Atherosclerosis Society

RESOURCES